The sequential changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy

Cancer

Volumn 77, Issue 6, 1996, Pages 1167-1179

  Takeda, Norio ^a,b   Diksic, Mirko ^a   Lucas Yamamoto, Y ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Yamagata Prefectural Central Hospital   (Japan)

Author keywords

Brain tumor; Chemotherapy; DNA synthesis; Glucose utilization; Peripheral benzodiazepine receptor; Protein synthesis

Indexed keywords

BENZODIAZEPINE RECEPTOR; BROXURIDINE; CARBON 14; CARMUSTINE; DEOXYGLUCOSE; DNA; GLUCOSE; NALPHA [N (2 CHLOROETHYL) N NITROSOCARBAMOYL]SARCOSINAMIDE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISSOCIATION CONSTANT; DNA SYNTHESIS; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GLIOMA; GLUCOSE UTILIZATION; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LABELING INDEX; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; BROMODEOXYURIDINE; CARMUSTINE; DNA; FEMALE; GLIOMA; GLUCOSE; IMMUNOHISTOCHEMISTRY; MONITORING, PHYSIOLOGIC; PROTEIN BIOSYNTHESIS; RATS; RATS, WISTAR; RECEPTORS, GABA-A;

EID: 0029987935     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960315)77:6<1167::AID-CNCR25>3.0.CO;2-Z     Document Type: Article

References (61)

1. Levin VA, Hoffman WF, Heilbron DC, Norman D. Prognostic significance of the pretreatment CT scan on time to progression. J Neurosurg 1980;52:642-7.
2. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant glioma: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1988;6:338-43.
3. Kimmel DW, Shapiro JR, Shapiro WR. Review article: in vitro drug sensitivity testing in human gliomas. J Neurosurg 1987;66:161-71.
4. Kornblith PL, Smith BH, Lonard LA. Response of cultured human brain tumors to nitrosoureas: correlation with clinical data. Cancer 1981;47:255-65.
5. Rosenblum ML, Gerosa MA. Stem cell sensitivity. Prog Exp Tumor Res 1984;28:1-17.
6. Ogawa T, Uemura K, Shishido F, Yamaguchi T, Murakami M, Inugami A, et al. Changes of cerebral blood flow, and oxygen and glucose metabolism following radiochemotherapy of gliomas: a PET study. J Comput Assist Tomogr 1988;12:290-7.
7. 11C]methionine. J Neurooncology 1986;3:397-404.
8. Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985;62:816-22.
9. Mineura K, Sasajima T, Kowada M, Ogawa T, Hatazawa J, Shishido F, et al. Perfusion and metabolism in predicting the survival of patients with cerebral gliomas. Cancer 1994;73:2386-94.
10. Miyazawa H, Arai T, Iino M, Hara T. PET Imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med 1993;34:1886-91.
11. Weizman R, Gavish M. Molecular cellular and behavioral aspects of peripheral-type benzodiazepine receptors. Clin Neuropharmacal 1993;16:401-17.
12. Takada A, Mitsuka S, Diksic M, Yamamoto YL. Autoradiographic study of peripheral benzodiazepine receptors in animal brain tumor models and human gliomas. Eur J Pharmacol - Environ Toxicol Pharmacol 1992;228:131-9.
13. Nagahiro S, Yamamoto YL, Diksic M, Mitsuka S, Sugimoto S, Feindel W. Neurotoxicity after intracarotid 1,3-bis(2-Chloroethyl)-1-nitrosourea administration in the rat: hemodynamic changes studied by double-tracer autoradiography. Neurosurgery 1991;29:19-25.
14. Skalski V, Rivas I, Panasci L, McQuillan A, Feindel W. The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man. Cancer Chemother Pharmacol 1988;22: 137-40.
15. Kato A, Diksic M, Yamamoto YL, Feindel W. Quantification of glucose utilization in an experimental brain tumor model by the deoxyglucose method. J Cereb Blood Flow Metabol 1985;5:108-14.
16. Mitsuka S, Diksic M, Takada A, Yamamoto YL. Influence of the tumor mass on the valine rate constants and on valine incorporation into proteins in an experimental brain tumor model. Neurochem Int 1992;20:537-51.
17. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
18. Radies C, Diksic M, Evans AC, Gjedde A, Yamamoto YL. Double-label autoradiographic deoxyglucose method for sequential measurement of regional cerebral glucose utilization. Neuroscience 1987;22:601-19.
19. Crane PD, Pardrige WM, Braun LD, Oldendorf WH. Kinetics of transport and phosphorylation of 2-fluoro-2-deoxy-D-glucose in rat brain. J Neurochem 1983;40:160-7.
20. Graham MM, Spence AM, Larson SM. Glucose metabolic rates in transplanted astrocytic gliomas in rats. J Cereb Blood Flow Metabol 1983;3(Suppl 1):S41-2.
21. Spence AM, Graham MM, Muzi M, Abbott GL, Krohn KA, Kapoor R, et al. Deoxyglucose lumped constant estimated in a transplanted rat astrocytic glioma by the hexose utilization index. J Cereb Blood Flow Metab 1990;10:190-8.
22. 14C] valine into protein in normal adult rat brain. J Cereb Blood Flow Metabol 1988;8:598-605.
23. Hoshino T, Nagashima T, Cho KG, Murovic JA, Hodes JE, Wilson CB, et al. S-phase fraction of human tumors in situ measured by uptake of bromodeoxyuridine. Int J Cancer 1986;38:369-74.
24. Dixon WJ. Nonparametric statistics in BMDP statistic software package. Dixon WJ, editor. Berkley: University of California Press, 1992:457-66.
25. Kew JFR, Winterford CM, Harmon BV. Apotosis. Its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
26. Kirikae M, Diksic M, Yamamoto YL. Quantitative measurements of regional glucose utilization and rate of valine incorporation into proteins by double-tracer autoradiography in the rat brain tumor model. J Cereb Blood Flow Metabol 1989;9:87-95.
27. Suami T, Kato T, Takino H, Hisamatu T. (2-Chioroethyl)-nitrosourea congeners of amino acid amides. J Med Chem 1982;25:829-32.
28. Panasci LC, Dufoux M, Chevalier L, Isabel G, Lazarus P, McQuillian A, et al. Utilization of HTSCA and CFV-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human gliomas compared with BCNU. Cancer Chemother Pharmacol 1985;14:156-9.
29. Houchens D, Nies R, Riblets S, Finfrok M, Trigg N. Immunodeficient animals in biochemical research. In: Wu BQ, Zheng J, editors. Sixth International Workshop on Immunodeficient Animals. Basel, Switzerland: Karger Publishing, 1989:157-61.
30. 11C-labelled BCNU and SarCNU in gliomas studied by PET. J Neurooncology 1991;10:47-55.
31. Fauchon F, Davila L, Chatellier G, Fohanno D, Philippon J, Rey A, et al. Treatment of malignant gliomas with surgery, intra-arterial infusion of 1-(2-Hydroxyethyl) chloroethyl nitrosourea, and radiation therapy: a phase II study. Neurosurgery 1990;27:231-4.
32. Shapiro WR, Green SB, Burger PC, Selker RG, VanGilder JC, Robertson JT, et al. A randomized comparison of intra-arterial versus intra-venous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992;76:772-81.
33. Yamada K, Ushio Y, Hayakawa T, Arita N, Huang T, Nagatani M, et al. Distribution of radiolabeled 1-(4-Amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride in rat brain tumor: intraarterial versus intravenous administration. Cancer Res 1987;47:2423-8.
34. Hoshino T, Ahn D, Prados MD, Lamborn K, Wilson C. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling. Int. J Cancer 1993;53:550-5.
35. Takeda N, Tanaka R, Fusejima T, Onda K, Hondo H. BrdU-labeling index and prognosis or radiosensitivity in glioma. The 49th Annual Meeting of the Japan Neurological Society. [Abstract I]. Neurol Med Chir 1990;30:126 (in Japanese).
36. Shields AF, Lim K, Grierson J, Link J, Krohn A. Utilization of labelled thymidine in DNA synthesis: studies for PET. J Nucl Med 1990;31:337-42-
37. Watanabe A, Tanaka R, Takeda N, Washiyama K. DNA synthesis, blood flow, and glucose utilization in experimental rat brain tumors. J Neurosurg 1989;70:86-91.
38. Weber MJ, Salter DW, McNair TE. Increased glucose transport in malignant cells: analysis of its molecular basis. In: Arnott MS, Van Eys J, Wang YM, editors. Molecular interrelations on nutrition and cancer. New York: Raven Press, 1982:183-90.
39. Packer RJ, Sutton LN, Goldwein JW, Perilongo G, Bunin G, Ryan J, et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medduloblastoma. J Neurosurg 1991;74:433-40.
40. Holzer T, Herholz K, Jeske J, Heiss WD. FDG-PET as a prognostic indicator in radiotherapy of glioblastoma. J Comput Assist Tomogr 1993;17:681-7.
41. Rozental JM, Cohen JD, Mehta MP, Levine RL, Hanson JM, Nickles RJ. Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. J Neurooncology 1993;15:57-66.
42. 11C]L-methionine PET in childhood brain tumors. Pediatr Neurol 1990;6:163-70.
43. 11C]-methionine. J Comput Assist Tomogr 1983;7:1062-6.
44. 11C-methyl]-L-methionine uptake of the glioma following radiotherapy. Jpn J Cancer Clin 1989;35:1101-4.
45. Lilja A, Bergstrom K, Hartvig P, Spannare B, Halldin C, Lundqvist H, et al. Dynamic study of supratentorial gliomas with L-methyl-11C-methionine and positron emission tomography. Am J Neuroradiol 1985;6:505-14.
46. Erikson K, Blomovist G, Bergstrom M, Eriksson L, Stone-Elander S. Application of a kinetic model on the methionine accumulation in intracranial tumors studied with positron emission tomography. Acta Radiol 1987;28:505-9.
47. Wan JM, Fogt F, Bistrian BR, Istfan NW. Evaluation of antitumor effect of tumor necrosis factor in terms of protein metabolism and cell cycle kinetics. Am J Physiol 1993;265: C365-74.
48. Starosta-Rubinstein S, Ciliax BJ, Penney JB, McKeever P, Young AB. Imaging of a glioma using peripheral benzodiazepine receptor ligands. Proc Natl Acad Sci USA 1987;84:891-5.
49. Black KL, Ikezaki K, Toga A. Imaging of brain tumors using peripheral benzodiazepine receptor ligands. J Neurosurg 1989;71:113-8.
50. Pappata S, Cornu P, Samson Y, Prenant C, Benavides B, Scatton B, et al. PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: a case report. J Nucl Med 1991;32:1608-10.
51. Parola AL, Yamamura HI, Hugh E, Laird H. Minireview. Peripheral-type benzodiazepine receptors. Life Sci 1993;52: 1329-42.
52. Matthew E, Laskin JD, Zimmerman EA, Weinstein IB, Hsu KC, Engelhardt DL. Benzodiazepines have high-affinity binding sites and induce melanogenesis in B16/C3 melanoma cells. Proc Natl Acad Sci USA 1981;78:3935-9.
53. Ikezaki K, Black KL. Stimulation of cell growth and DNA synthesis by peripheral benzodiazepine. Cancer Lett 1990; 49:115-20.
54. Katz Y, Ben-Baruch G, Kloog Y, Menczer J, Gavish M. Increased density of peripheral benzodiazepine-binding sites in ovarian carcinomas as compared with benign ovarian tumors and normal ovaries. Clin Sci: 1990;78:155-8.
55. Katz Y, Eitan A, Gavish M. Increase in peripheral benzodiazepine binding sites in colonic adenocarcinoma. Oncology 1990;47:139-42.
56. 14C]-deoxyglucose metabolism and peripheral benzodiazepine receptor binding in rat C6 glioma. Neurology 1988;38:1255-62.
57. Allam A, Taghian A, Gioioso D, Duffy M, Suit HD. Intratumoral heterogeneity of malignant gliomas measured in vitro. Int J Radia Oncol Biol Phys 1993;27:303-8.
58. Twentyman PR, Bleehen NM. Changes in sensitivity to radiation and to bleomycin occurring during the life history of monolayer cultures of a mouse tumor cell line. Br J Cancer 1975;31:68-74.
59. Allalunis-Turner MJ, Barron GM, Day RS, Dobler KD, Mirzayans R. Isolation of two cell lines from a human malignant specimen differing in sensitivity to radiation and chemotherapeutic drugs. Radiat Res 1993;134:349-54.
60. 13C-n. m. r. spectroscopy. Biochem J 1990;266:133-9.
61. 18F-fluoro-2′-deoxyuridine as a tracer of nucleic acid metabolism in brain tumors. J Neurosurg 1990;72:110-3.